• HIV infection:
    • Adults: PO 300mg OD
    • ≥2 years and weigh (≥10 kg): PO 8mg/kg OD
      • Max 300 mg/day
  • Chronic Hepatitis B infection:
    • PO 300mg OD
    • ≥2 years and weigh (≥10 kg): PO 8mg/kg OD
      • Max 300 mg/day
  • HIV post-exposure prophylaxis (Off-label):
    • PO 300mg OD
    • ≥2 years and weigh (≥10 kg): PO 8mg/kg OD
      • Max 300 mg/day
  • Perinatal transmission Hepatitis B infection prophylaxis (Off-label):
    • PO 300mg OD
    • Initially at 28-32 week gestation
    • For pregnant patients with HBV DNA >200,000
    • 1st-line agent
    • Discontinue between birth to 3 months postpartum

Tablet: 300mg

  • To be taken with/without food
  • Administer at least 2 hours before or 1 hours after didanosine

Nucleoside Reverse Transcriptase Inhibitor (NRTI)

Analog of adenosine 5′-monophosphate that inhibits HIV-1 reverse transcriptase by competing with AMP as substrate, which results in the inhibition of viral replication

  • Rash
  • Hypercholesterolemia
  • Headache
  • Elevated CK
  • Pain
  • Diarrhea
  • Depression
  • Hyperamylasemia
  • Back pain
  • Fever
  • Nausea
  • Vomiting
  • Fatigue
  • URI
  • Abdominal pain
  • Hematuria
  • Asthenia
  • Anxiety
  • Arthralgia
  • Myalgia
  • Insomnia
  • Pruritus
  • Pneumonia
  • Dyspepsia
  • Dizziness
  • Elevated ALT/AST
  • Glycosuria
  • Neutropenia
  • Increased Cr
  • Bone density loss
  • Recent or concurrent nephrotoxic agent use
  • CrCl <10 (patients not on hemodialysis)

WARNING

Severe acute exacerbations of hepatitis may occur in HBV-infected patients when tenofovir is discontinued

  • Elvitegravir/cobicistat/emtricitabine/tenofovir df
  • Streptozocin
  • Cidofovir

                          Drug Status

Availability Prescription only
Pregnancy Benefits outweigh risks
Breastfeeding Nursing contraindicated
Schedule Not controlled
BRAND NAME STRENGTH FORMULATION PACK SIZE MANUFACTURER DISTRIBUTOR
Viread 300mg Tablet 30’s Gilead Sciences Phillips Therapeutics